The associations of pneumonia with cardiac injury and new-onset heart failure

Not Applicable

• Conditions: Community-acquired pneumonia; New-onset chronic heart failure; Myocardial fibrosis; Respiratory - Other respiratory disorders / diseases; Cardiovascular - Other cardiovascular diseases; Infection - Other infectious diseases

• Registration Number: ACTRN12622001412729
• Lead Sponsor: Dr Adil Rajwani

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-11-04
• Last Update Posted: 14 November 2022

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 138

Inclusion Criteria

(i) Adults hospitalised with community-acquired pneumonia (meeting American Thoracic Society criteria in terms of clinical presentation and radiological features);
(ii) Capacity to provide written informed consent.

Exclusion Criteria

Viral pneumonia, based on the detection of viral nucleic acid amplification on admission screening for pneumonia pathogens.

Prior clinical history of coronary artery disease, myocarditis, connective tissue disorders, cardiomyopathy, heart failure, or pre-existing requirement for loop diuretics.

Left ventricular ejection fraction <54% (women) or <52% (men) at baseline echocardiogram.

Contraindications to contrast-enhanced CMR including prohibitive implanted ferromagnetic devices, pregnancy, severe claustrophobia, and chronic kidney disease with estimate glomerular filtration rate <=30ml/min/1.73msq.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of myocardial fibrosis as detected by gadolinium contrast-enhanced CMR[2-4 weeks after discharge from the index hospitalisation for community-acquired pneumonia.]